Boston Scientific Corporation
BSX
$100.02
$0.970.98%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.62% | 21.45% | 19.35% | 17.60% | 15.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.62% | 21.45% | 19.35% | 17.60% | 15.65% |
| Cost of Revenue | 23.23% | 23.95% | 21.47% | 20.47% | 16.82% |
| Gross Profit | 20.89% | 20.31% | 18.40% | 16.32% | 15.13% |
| SG&A Expenses | 15.91% | 19.44% | 16.45% | 15.30% | 15.62% |
| Depreciation & Amortization | 6.43% | 3.68% | 2.62% | 3.38% | 2.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.47% | 20.75% | 17.46% | 16.25% | 14.43% |
| Operating Income | 31.59% | 24.65% | 28.48% | 24.22% | 21.64% |
| Income Before Tax | 48.39% | 39.93% | 15.30% | 14.95% | 17.43% |
| Income Tax Expenses | 17.15% | 57.37% | 20.42% | 10.94% | -36.01% |
| Earnings from Continuing Operations | 55.62% | 36.88% | 14.21% | 15.94% | 45.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 100.00% | 100.00% | 300.00% | 600.00% | -- |
| Net Income | 55.72% | 37.01% | 14.54% | 16.31% | 45.89% |
| EBIT | 31.59% | 24.65% | 28.48% | 24.22% | 21.64% |
| EBITDA | 24.87% | 19.18% | 21.23% | 18.22% | 16.00% |
| EPS Basic | 54.66% | 36.08% | 14.20% | 16.72% | 48.46% |
| Normalized Basic EPS | 47.46% | 43.48% | 32.13% | 28.95% | 23.34% |
| EPS Diluted | 54.79% | 36.54% | 15.06% | 16.87% | 47.85% |
| Normalized Diluted EPS | 47.33% | 43.24% | 31.81% | 28.65% | 23.10% |
| Average Basic Shares Outstanding | 0.61% | 0.60% | 0.86% | 1.27% | 1.69% |
| Average Diluted Shares Outstanding | 0.71% | 0.78% | 1.11% | 1.53% | 1.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -1.00% |